

Anti-DR4/TRAIL R1 Antibody-PE (6F81)

Product Details

Ig Type:	Mouse IgG1
Reactivity:	Human
Conjugation:	PE
Clone:	6F81
Purification:	Protein A

Applications

Verified Activity:	Flow cytometric analysis of human TNFRSF10A(CD261) expression on HeLa cells. HeLa cells were stained with PE-conjugated anti-Human TNFRSF10A(CD261). The histogram were derived from gated events with the forward and side light-scatter characteristics of intact cells.
Application:	FCM
Recommended	10 µl/Test, 0.1 mg/ml

Properties

Stability & Storage:	Store at 2°C-8°C for 12 months, do not freeze. Keep away from direct sunlight. Sodium azide is toxic to cells and should be disposed of properly. Flush with large volumes of water during disposal.
Shipping:	Shipping with blue ice.

Antigen Details

Immunogen:	Recombinant Protein: Human TRAIL R1 / CD261 / TNFRSF10A protein (TMPY-01720)
Antigen Species:	Human
Synonyms:	APO2;TRAILR-1;DR4;tumor necrosis factor receptor superfamily member 10a;TRAILR1;MGC9365;TNFRSF10A;CD261
Biology Area:	Cancer Drug Targets

Research Background

Tumor necrosis factor receptor superfamily, member 10a (TRAIL R1), also known as TRAIL receptor 1 (TRAIL R1) or CD261 antigen, is a member of the TNF-receptor superfamily. This receptor is activated by tumor necrosis factor-related apoptosis inducing ligand (TNFSF10/TRAIL), and thus transduces cell death signal and induces cell apoptosis. Studies with FADD-deficient mice suggested that FADD, a death domain containing adaptor protein, is required for the apoptosis mediated by this protein. TRAIL R1/CD261/TNFRSF10A serves as a receptor for the cytotoxic ligand TNFSF10/TRAIL. The adapter molecule FADD recruits caspase-8 to the activated receptor. The resulting death-inducing signaling complex (DISC) performs caspase-8 proteolytic activation which initiates the subsequent cascade of caspases (aspartate-specific cysteine proteases) mediating apoptosis. TRAIL R1 can promote the activation of NF-kappa-B. TRAIL R1/CD261/TNFRSF10A induces apoptosis of many transformed cell lines but not of normal tissues, even though its death domain-containing receptor, DR4, is expressed on both cell types. Cancer Immunotherapy/Immune Checkpoint Immunotherapy/Targeted Therapy

Inhibitor · Natural Compounds · Compound Libraries · Recombinant Proteins

This product is for Research Use Only · Not for Human or Veterinary or Therapeutic Use

Tel:781-999-4286 E_mail:info@targetmol.com Address:34 Washington Street,Wellesley Hills,MA 02481